Plimoth Trust Co. LLC Has $3.77 Million Stake in Stryker Co. (NYSE:SYK)

Plimoth Trust Co. LLC increased its position in shares of Stryker Co. (NYSE:SYK) by 0.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,457 shares of the medical technology company’s stock after buying an additional 65 shares during the period. Plimoth Trust Co. LLC’s holdings in Stryker were worth $3,765,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in SYK. State Street Corp boosted its position in Stryker by 2.2% during the third quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock worth $5,279,788,000 after purchasing an additional 316,404 shares during the period. FMR LLC boosted its position in Stryker by 3.0% during the third quarter. FMR LLC now owns 7,306,994 shares of the medical technology company’s stock worth $2,639,725,000 after purchasing an additional 215,782 shares during the period. Geode Capital Management LLC boosted its position in Stryker by 2.5% during the third quarter. Geode Capital Management LLC now owns 6,905,126 shares of the medical technology company’s stock worth $2,484,893,000 after purchasing an additional 165,490 shares during the period. Clearbridge Investments LLC boosted its position in Stryker by 2.9% during the second quarter. Clearbridge Investments LLC now owns 2,323,452 shares of the medical technology company’s stock worth $790,554,000 after purchasing an additional 66,482 shares during the period. Finally, Parnassus Investments LLC bought a new position in Stryker during the third quarter worth $762,798,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 5.50% of the stock is owned by corporate insiders.

Stryker Stock Down 1.3 %

NYSE SYK traded down $5.17 on Wednesday, reaching $389.98. The company had a trading volume of 469,815 shares, compared to its average volume of 1,426,831. The stock has a market capitalization of $148.67 billion, a P/E ratio of 41.79, a P/E/G ratio of 2.68 and a beta of 0.95. The company’s fifty day moving average is $376.44 and its 200 day moving average is $361.98. Stryker Co. has a 52-week low of $314.05 and a 52-week high of $406.19. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.07% and a net margin of 16.34%. During the same quarter last year, the firm posted $3.46 earnings per share. Sell-side analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a $0.84 dividend. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 annualized dividend and a yield of 0.86%. This is an increase from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio (DPR) is currently 36.01%.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of recent research reports. Barclays boosted their target price on shares of Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a research report on Thursday, October 31st. Robert W. Baird boosted their target price on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. JMP Securities reissued a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Wednesday, January 22nd. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $425.00 target price on shares of Stryker in a research report on Tuesday, January 7th. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $412.55.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.